Fluvoxamine alters the activity of energy metabolism enzymes in the brain

Objective: Several studies support the hypothesis that metabolism impairment is involved in the pathophysiology of depression and that some antidepressants act by modulating brain energy metabolism. Thus, we evaluated the activity of Krebs cycle enzymes, the mitochondrial respiratory chain, and crea...

Full description

Bibliographic Details
Main Authors: Gabriela K. Ferreira, Mariane R. Cardoso, Isabela C. Jeremias, Cinara L. Gonçalves, Karolina V. Freitas, Rafaela Antonini, Giselli Scaini, Gislaine T. Rezin, João Quevedo, Emilio L. Streck
Format: Article
Language:English
Published: Associação Brasileira de Psiquiatria (ABP) 2014-09-01
Series:Brazilian Journal of Psychiatry
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462014000300220&lng=en&tlng=en
Description
Summary:Objective: Several studies support the hypothesis that metabolism impairment is involved in the pathophysiology of depression and that some antidepressants act by modulating brain energy metabolism. Thus, we evaluated the activity of Krebs cycle enzymes, the mitochondrial respiratory chain, and creatine kinase in the brain of rats subjected to prolonged administration of fluvoxamine. Methods: Wistar rats received daily administration of fluvoxamine in saline (10, 30, and 60 mg/kg) for 14 days. Twelve hours after the last administration, rats were killed by decapitation and the prefrontal cortex, cerebral cortex, hippocampus, striatum, and cerebellum were rapidly isolated. Results: The activities of citrate synthase, malate dehydrogenase, and complexes I, II-III, and IV were decreased after prolonged administration of fluvoxamine in rats. However, the activities of complex II, succinate dehydrogenase, and creatine kinase were increased. Conclusions: Alterations in activity of energy metabolism enzymes were observed in most brain areas analyzed. Thus, we suggest that the decrease in citrate synthase, malate dehydrogenase, and complexes I, II-III, and IV can be related to adverse effects of pharmacotherapy, but long-term molecular adaptations cannot be ruled out. In addition, we demonstrated that these changes varied according to brain structure or biochemical analysis and were not dose-dependent.
ISSN:1809-452X